This inventor holds 6 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Merus N.v.. Active years: 2023-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
5 out of 48 
Years Active: 2023-2026
Title: Paulus Johannes Tacken: Innovator in Antibody Therapeutics
Introduction
Paulus Johannes Tacken is an esteemed inventor based in Utrecht, Netherlands, recognized for his significant contributions to the field of biotechnology. With a portfolio of four patents, he plays a pivotal role in advancing therapeutic solutions through innovative antibody designs.
Latest Patents
Tacken's most recent patents underscore his expertise in immunotherapy. One of his notable inventions is the development of bispecific anti PD1-anti TIM3 antibodies. This patent addresses methods to interfere with the Programmed Cell Death 1 (PD-1) protein and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition. The invention details methods where cells can be contacted with antibodies that target both PD-1 and TIM-3, effectively inhibiting their mediated activities.
In addition, Tacken has been involved in creating antibodies that modulate biological activity expressed by cells. This patent focuses on methods to counteract PD-1 and Lymphocyte activation 3 (LAG-3) mediated inhibition, further demonstrating his commitment to enhancing therapeutic options through innovative antibody technologies.
Career Highlights
Paulus Johannes Tacken is affiliated with Merus N.V., a company dedicated to developing innovative immunotherapies for cancer treatment. His work and patents significantly contribute to advancing the understanding and treatment of various forms of cancer through novel antibody approaches.
Collaborations
Throughout his career, Tacken has collaborated with notable colleagues, including Cecilia Anna Wilhelmina Geuijen and Rinse Klooster. These partnerships highlight the collaborative spirit inherent in scientific research and innovation, fostering an environment where new ideas and solutions can flourish.
Conclusion
Paulus Johannes Tacken exemplifies the spirit of innovation within the pharmaceutical industry. His work on bispecific antibodies and methods to inhibit key proteins in cancer therapy has set the stage for potential breakthroughs in treating complex diseases. With his continued efforts and collaborations, Tacken remains at the forefront of developing impactful therapeutic strategies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile